Latest News

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

• share
• favorite_border

Expert can speak on the promise of vaccines to counter heroin addiction and broader efforts to address opioid addiction. Roger Crystal, M.D., CEO of Opiant Pharmaceuticals, has an interest in this area inspired by his company’s own efforts to develop opioid antagonist nasal sprays and other innovative formulations for the treatment of substance abuse disorders, addictive disorders and eating disorders.

• share
• favorite_border

Expert can speak on the use of animal toxins to develop a new generation of medicines. Gur Roshwalb, MD, Chief Executive Officer of Akari Therapeutics, is studying the use of Coversin—a molecule derived from the saliva of the Ornithodoros moubata tick—in potential treatments for conditions such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and Guillain Barré syndrome (GBS).

• share
• favorite_border

Expert can speak on the importance of including women in clinical studies, a measure that could lead to improved, women-specific treatments. Brad Thompson, Ph.D., president and CEO of Oncolytics Biotech Inc., has overseen studies in colorectal cancer and non-small cell lung cancer in which female patients showed a significant response (relative to male patients) to a treatment that included the company’s lead product, REOLYSIN®, a proprietary formulation of the human reovirus.

• share
• favorite_border

Expert can speak about the need for better treatment of complex regional pain syndrome (CRPS), a chronic condition most often affecting one of the limbs (arm, leg, hand or foot), usually after an injury or trauma to that limb. Randall Kaye, M.D. of Axsome Therapeutics can describe the characteristics of CRPS, discuss the many stories from patients describing their pain, and detail a clinical study Axsome is conducting a study on what could be the first-ever approved medication for the condition.

• share
• favorite_border

Expert can speak on the use of EEG measurements to predict how individuals will respond to specific medical treatments. Specifically, MYnd Analytics has developed the PEER Online platform, allowing doctors to compare patients’ EEGs to a growing database that correlates specific EEG patterns with positive and negative responses to a range of psychotropic medications. As a result, doctors can use evidence-based medicine to reduce the traditional “trial and error” approach to prescribing for mental health.

• share
• favorite_border

Expert can discuss recent advances in the science of bioanalytics and molecular information, that let us identify and characterize the products of all living cells—including proteins, lipids, metabolites and nucleic acids. He can specifically focus on how this technology is becoming a key driver in basic research, pharmaceutical development and clinical medicine.

• share
• favorite_border

Experts can speak on the factors contributing to the rise in popularity of walk-in urgent care and primary care centers across the U.S., as well as the future growth of this sector and the business potential associated with consolidation among urgent care networks.

• share
• favorite_border

Expert can discuss the potential synergies between CRISPR (and other gene editing tools) and the AdenoVerse gene delivery technology platform developed by GenVec, Inc. The AdenoVerse platform has demonstrated an outstanding ability to deliver complex genes and works with a variety of strategies for therapeutics and vaccines, including gene editing tools—not only CRISPR but also TALEN, Zinc Finger, ARCUS and others.

• share
• favorite_border

After Cynthia Vetter’s husband—a highway patrol officer—was fatally shot in Texas during a routine traffic stop in 2000, the tragedy inspired the creation of Dallas-based COPsync, Inc. The company has created the COPsync Network, with applications that enable law enforcement patrol officers to communicate in real-time on the Network; and COPsync911, which is activated by school staff when a threatening situation arises, and allows the staff to send an immediate and silent alert to all other staff, the local law enforcement dispatch center and the closest law enforcement officers in their patrol cars.

• share
• favorite_border

Expert can discuss drone package delivery and why launching delivery drones from local delivery trucks can make the drone flights short, effective, safe and extremely economical.

• share
• favorite_border

Expert can discuss the ways in which industries that produce low-BTU waste gases (such as methane) can remain profitable even while adopting the EPA’s new Clean Power Plan, and how the technology developed by his company, Ener-Core, Inc., can play a key role in effective this positive change.

• share
• favorite_border

Expert can speak about the need for better technological solutions to keep law enforcement officers safe to help them interdict criminals traveling throughout the U.S., as well as systems such as the COPsync Network that are already in use in various states.

• share
• favorite_border

Expert can discuss the need to address the issue of heroin and prescription opioid abuse by developing innovative medical treatments. Specifically, he can describe the features and benefits of an inside-the-cheek format of buprenorphine for the maintenance treatment of opioid addiction.

• share
• favorite_border

Expert can discuss school safety and how a new technology, the COPsync911 threat notification system, that connects a school or other facility under threat directly to the closest patrol officers and local dispatch during an episode of violence—ensuring law enforcement is on the scene faster than 911—and potentially mitigating the liability faced by schools in states like Colorado, which have passed legislation to allow lawsuits against schools when shootings or other violence occurs.

• share
• favorite_border

Expert can speak on the need for treatment of pain with less potential for abuse than existing painkillers; for better options for those already dealing with opioid dependence; and for the need to address patients’ lifestyles as well as bodies to ensure optimal treatment. Dr. Mark Sirgo is president and CEO of BioDelivery Sciences, whose FDA-approved drug BUNAVAIL and investigational drug BELBUCA allow for the efficient delivery of buprenorphine while potentially overcoming some of the administration challenges presented by sublingual dosage forms, and whose Inreach Assist website and app offers a comprehensive array of information and resources to support patients dealing with addiction and their families.

• share
• favorite_border

An expert can speak on how treating sleep problems might reduce the potential of PTSD among military personnel. Seth Lederman, MD, co-founder and CEO of Tonix Pharmaceuticals Holding Corp., is overseeing the development of TNX-102 SL, an advanced sublingual reformulation of the FDA-approved muscle relaxant cyclobenzaprine, aiming to improve sleep quality and make a meaningful difference in the symptoms experienced by PTSD patients. Tonix’s AtEase Study is a Phase 2 clinical study to evaluate the potential therapeutic benefits of TNX-102 SL for PTSD in members of the military and its veterans.

• share
• favorite_border

Expert can discuss Microsoft’s recent announcement that it will require many of its 2,000 contractors and vendors to provide their employees with 15 paid days off for sick days and vacation time. As CEO of Atrium Staffing in New York City, Cenni is an expert at the issues surrounding the status of contract workers and the challenges facing companies that want to obey employment laws.

• share
• favorite_border

Expert can speak on the advantages of having police officers use new electronic data-sharing technologies to apprehend criminals more efficiently. Ronald Woessner, CEO of COPsync, Inc., has helped develop a real-time, in-car information-sharing communication and data interoperability network enabling patrol officers to collect, report and share critical data in real-time at the point of incident and obtain instant access to various databases.

• share
• favorite_border

Expert can speak on commercially available technology that harnesses the methane waste gases produced by various industries and converts it into clean energy that a business can use on-site or sell for a profit—all while using its current infrastructure. Alain Castro is the CEO of Ener-Core, Inc., which has developed and is now commercializing its Power Oxidizer, which converts low quality waste gases such as methane into useful heat and power.

• share
• favorite_border

Experts can discuss the prediction that Americans may spend $4.8 billion on jewelry this Valentine’s day, and why moissanite, the world’s most brilliant gem®, represents one of the most economically sensible choices for this type of gift.

• share
• favorite_border

Expert can harness her extensive experience working with addiction and mental health a residential treatment center in Canada to discuss the implications of a sharp rise in the use of marijuana among the adult population in Ontario, and whether marijuana has been given a “free pass” as a largely harmless drug leading to greater consequences.

• share
• favorite_border

Many Americans find it increasingly appealing to learn about wealth strategies in a group of like-minded students. Throughout 2015, workshops conducted across the U.S. and around the globe by Rich Dad Education will present invaluable tips designed to help novice stock traders and real estate investment beginners—as well as those who have made a few investments but are looking for ways to increase their skills.

• share
• favorite_border

On January 23, 2015, the National Association of Realtors will release its first report of the year, covering sales for the month of December 2014. The report will likely set the tone for home sales during the new year. Anthony Humpage, CEO at Legacy Education Alliance, Inc., can comment on why MORE is better than BIG—i.e., why, in the realm of real estate, it is far wiser to take advantage of low interest rates on mortgages by investing in rental properties rather than buying or building a bigger home, as many people choose.

• share
• favorite_border

The classic, 20th-century ideal of employment—one full-time job for every worker—is dying. The new paradigm, dubbed the 1099 economy, makes it easier for creative individuals to carve a niche (or two or three) that reflects their interests. But success means knowing how to handle money issues. That’s where Rich Dad Education comes in. Based on the teachings of Robert Kiyosaki, author of revolutionary bestseller Rich Dad, Poor Dad, Rich Dad Education is dedicated to elevating the financial well-being of people from all walks of life.

• share
• favorite_border

Expert can speak about Google’s plans to develop tiny magnetic particles to patrol the body for signs of cancer and other diseases, and a wearable device with a magnet to attract and count the particles as a monitoring tool. Edward Flynn, Ph.D. has years of experience developing a similar nanotech-based cancer detection system at Senior Scientific, a subsidiary of Manhattan Scientifics.

• share
• favorite_border

New and more effective treatments for diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs) are sorely needed. One of the today’s most promising approaches harnesses regenerative medicine, specifically cell therapy. Israel-based Macrocure Ltd.’s lead product, CureXcell™, harnesses living white blood cells, including macrophages, neutrophils and lymphocytes, that are crucial to initiating, promoting and completing the process of cellular regeneration and wound healing for both of these conditions.

• share
• favorite_border

The U.S. Navy and Office of Naval Research are developing unmanned surface vehicle (USV) technology that allows USVs to act in tandem as an autonomous “swarm” of robot boats potentially providing enhanced security against enemy vessels. But the USV technology suffers from technical hurdles, including a lack of a stable platform required for proper communication among the boats. The Ghost—a high-speed attack craft designed by Juliet Marine Systems to protect vital waterways—offers a potential alternative, with stability on the water that the USV technology needs.

• share
• favorite_border

Researchers have known that treating a pancreatic cancer patient with human reovirus is only likely to be effective if the patient carries the mutant KRAS gene and not the wild-type KRAS gene. A recent Phase 2 clinical study by Oncolytics Biotech, Inc., involving their proprietary form of the human reovirus, REOLYSIN®, has corroborated this link, pointing the way toward more personalized cancer care if mutant KRAS is used as a biomarker and prospective patients are screened in advance of treatment.

• share
• favorite_border

Expert can speak on the latest round of funding of SideCar, a disruptive ride-sharing app, including Richard Branson’s participation as investor. Rich Levandov, a partner in Avalon Ventures, one of the venture capital firms behind the new $15M round of funding of SideCar, has decades of experience in funding promising early-stage companies and can describe what features make a startup worth investing in, especially in the areas of IT and biotech.

• share
• favorite_border

Expert can speak on the challenge of calculating beforehand the likelihood that a particular woman’s breast cancer will metastasize or not, and how new tests might offer a way forward. MetaStat, Inc., a life sciences company, is developing new tests for women with breast cancer to analyze whether their tumors have metastatic potential, MetaSite Breast and MenaCal. These tests are intended to potentially allow clinicians to customize cancer treatment decisions by identifying and differentiating high-risk patients who need aggressive therapy, and by possibly sparing low-risk patients from the harmful side effects and expense of chemotherapy and mastectomy.

• share
• favorite_border

Expert is available to comment on the impending likely approval of Merck & Co.’s immuno-oncology drug, pembrolizumab, as a treatment for melanoma. According to Dr. Robert H. Pierce of OncoSec Medical, it is believed that 60 to 70 percent of patients with metastatic melanoma exhibit no response to anti-PD-1 immunotherapy that Merck is developing, so it could be useful to combine it with other forms of immunotherapy. One such alternate form is OncoSec’s ImmunoPulse, which delivers brief electrical pulses of DNA IL-12 and has shown in early studies to date to penetrate and destroy cancer cells.

• share
• favorite_border

A research team led by Raymond Tak Fai Cheung, PhD and student Lynn Yan-Hua Sang, PhD of the University of Hong Kong suggests a new therapeutic strategy for intracerebral hemorrhage: injecting self-assembling peptide nanofiber scaffolds (SAPNS) directly into a hemorrhagic lesion.

• share
• favorite_border

Expert can speak on the risks involved in the use of topical corticosteroids, prescriptions of which have risen sharply in the past few years, as well as on the development of new topical non-steroidal Multi-Functional Anti-Inflammatory Drugs that address the symptoms of inflammation without the attendant side effects linked to steroids.

• share
• favorite_border

Rheumatology expert is available to offer commentary about the recent FDA public meeting on fibromyalgia (FM), including shortcomings in the current treatment paradigm for people with FM, why focusing on sleep quality could be the key to better treatment and what advances are being made on the frontiers of research today.

• share
• favorite_border

Carbs come in a dizzying variety of sizes and shapes, and due to this diversity, researchers can use them to create a broad range of drugs—including some that can address the complications of diabetes. Boston Therapeutics’ compound BTI20 is a new compound designed to keep blood sugar after eating from spiking and could prevent or at least delay the onset of Type 2 diabetes.

• share
• favorite_border

Among the surgical community there is a growing need for better hemostatic (stopping bleeding) solutions. To address this need, Arch Therapeutics, Inc. is creating its first product, AC5 Surgical Hemostatic Device™. Currently in preclinical development, AC5 is designed to achieve hemostasis in minimally invasive and open surgical procedures, and it offers a number of advantages over products currently on the market.

• share
• favorite_border

Dr. David Platt, scientific pioneer, author and expert, can discuss the study “Added Sugar Intake and Cardiovascular Diseases Mortality Among US Adults” published in JAMA, and can provide insightful information on how sugar enters the body from carbohydrates, and tips for fighting rises in blood sugar which is a factor that can lead to many chronic conditions.

• share
• favorite_border

An increasing number of prospective patients for bone marrow transplant are over age 55, but many in this group who need it are ruled ineligible because high-dose chemotherapy traditionally preceding it is in many cases lethal to such patients. Actinium Pharmaceuticals, Inc., a New York City-based biotech company, has developed a treatment in which a patient can be prepared for a transplant in a way that eliminates the need for multiple rounds of high-dose chemotherapy.

• share
• favorite_border

Google recently announced contact lenses for diabetes patients that can monitor blood glucose levels in tears. Yet Google is far from the only company innovating pain-free, non-needle glucose measurement systems. Integrity Applications has created the GlucoTrack® model DF-F noninvasive blood glucose measurement device, which takes advantage of the natural physiology of the ear lobe and uses an ear lobe clip to deliver blood glucose readings in about a minute.

• share
• favorite_border

Drug industry veteran can speak about the rapidly growing and evolving pet therapeutics market and the specific challenges of developing new prescription treatments for dogs, cats and horses—an area that has been traditionally underserved by the medical research community.

• share
• favorite_border

When Jeffrey A. Duchemin arrived as Chief Executive Officer at Holliston, MA-based Harvard Bioscience in August, it represented more than just a new job for the veteran life sciences executive. In an era of rapid transformation within the field, it put Duchemin at the helm of a leading source of innovation.

• share
• favorite_border

ID verification expert, Nelson Ludlow, can speak about a new smartphone app, barZapp™, that scans the barcode on a driver’s license or other ID and can instantly verify authenticity—a tool that could be used in New York City in an effort to enforce the new ban on tobacco sales to those under the age of 21.

• share
• favorite_border

Today, customers of diamonds and other jewelry can buy in a traditional store or through a variety of new outlets including cable TV and the Internet. Randall McCullough, the President & CEO of Charles & Colvard, the exclusive global supplier of moissanite, is keeping tabs on how these new options are changing the market. Moissanite—10 percent more brilliance than its diamond counterpart at 1/10 the price!—is rapidly growing its appeal to female and male customers via a range of domestic and international retailers and other sales channels.